PATRICK VERMETTE

Development of a new matrix for pancreatic islets culture and its validation in a bioartificial pancreas (BioArtMatrix)

Competition : Quantum Leap Québec –  France 2013 Funding : $1,133,800 / 3 years Beginning : September 2014 Platform technology to (i) detect antidrug antibodies with unprecedented sensitivity and (ii) predict cellular-mediated immunological mechanisms using bioactivated low-fouling surfaces combined with quartz crystal microbalance (QCM). Islet transplantation consists in the replacement of deficient cells in type 1 diabetic patients. This therapy … Read More

*EUSTACHE PARAMITHIOTIS

Development of biomarkers for measurement of early stage diabetes disease and for prediction of response to therapy

Competition: FOCUS Program 2009 Funding: $2,360,000 / 3 years  Beginning: September 2014 (COMPLETED PROJECT) Relying on Caprion’s CellCarta proteomics technology to develop panels of protein diabetes biomarkers, this project will improve early diagnosis and monitor disease progression, as well as, evaluate therapeutic response. Overview A unique panel of clinically validated pancreatic ß-cell biomarkers readily detected in blood were discovered which … Read More

PAVEL HAMET

A genetic test to predict diabetic nephropathy in Type 2 diabetes patients

Competition: SynergiQc 2017 Funding: $683,665 / 2 years Beginning: July 2017 Challenge: Occurrence of type 2 diabetes (T2D) is increasing worldwide, and particularly among younger subjects who are more susceptible to renal complications that can lead to renal failure. Such diabetic nephropathy (DN) is present in about 40% of T2D patients. Treatments exist to control renal damage due to T2D … Read More